Pancreatic Islet Responses to Metabolic Trauma

Shock

Volumn 46, Issue 3, 2016, Pages 230-238

  Burke, Susan J ^a   Karlstad, Michael D ^b   Jason Collier, J ^a,b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; insulin resistance; metabolic disease; metabolism; obesity; proliferation

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; FIBROBLAST GROWTH FACTOR 21; GLUCOCORTICOID; GLUCOSE TRANSPORTER 4; INSULIN; NEUROLEPTIC AGENT;

CARDIOGENIC SHOCK; CRITICAL ILLNESS; CUSHING SYNDROME; ENDOCRINE PANCREAS; GENE DELETION; GLUCOSE HOMEOSTASIS; HUMAN; INFLAMMATION; INJURY; INSULIN RELEASE; INSULIN RESISTANCE; LIPODYSTROPHY; METABOLIC DISORDER; METABOLISM; NONHUMAN; OBESITY; ORGAN SIZE; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PHARMACEUTICAL CARE; REVIEW; ANIMAL; DRUG EFFECTS; GENETICS; PHYSIOLOGY;

ANIMALS; ANTIPSYCHOTIC AGENTS; GLUCOCORTICOIDS; HUMANS; INSULIN RESISTANCE; ISLETS OF LANGERHANS; LIPODYSTROPHY; OBESITY;

EID: 84961219152     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000607     Document Type: Review

References (122)

1. Bonner-Weir S, Sullivan BA, Weir GC: Human islet morphology revisited: human and rodent islets are not so different after all. J Histochem Cytochem 63(8):604-612, 2015.
2. Defronzo RA: Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58(4):773-795, 2009.
3. Unger RH: Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 14(9):398-403, 2003.
4. Cefalu WT: Insulin resistance: cellular and clinical concepts. Exp Biol Med (Maywood) 226(1):13-26, 2001.
5. Glass CK, Olefsky JM: Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 15(5):635-645, 2012.
6. Samuel VT, Shulman GI: Mechanisms for insulin resistance: common threads and missing links. Cell 148(5):852-871, 2012.
7. Haslam DW, James WP: Obesity. Lancet 366(9492):1197-1209, 2005.
8. Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89(6):2548-2556, 2004.
9. Grant RW, Dixit VD: Adipose tissue as an immunological organ. Obesity (Silver Spring) 23(3):512-518, 2015.
10. Ogilvie RF: The islands of langerhans in 19 cases of obesity. J Pathol Bacteriol 37(3):473-481, 1933.
11. Saisho Y, Butler AE, Manesso E, Elashoff D, Rizza RA, Butler PC: Beta-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care 36(1):111-117, 2013.
12. Hellerstrom C, Hellman B: The Islets of Langerhans in yellow obese mice. Metabolism 12:527-536, 1963.
13. Gonet AE, Stauffacher W, Pictet R, Renold AE: Obesity and diabetes mellitus with striking congenital hyperplasia of the islets of langerhans in spiny mice (Acomys Cahirinus): I. Histological findings and preliminary metabolic observations. Diabetologia 1(3-4):162-171, 1966.
14. Storlien LH, James DE, Burleigh KM, Chisholm DJ, Kraegen EW: Fat feeding causes widespread in vivo insulin resistance, decreased energy expenditure, and obesity in rats. Am J Physiol 251(5 Pt 1):E576-E583, 1986.
15. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN: Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37(9):1163-1167, 1988.
16. Kahn SE, Cooper ME, Prato Del S: Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383(9922): 1068-1083, 2014.
17. Kahn BB: Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. Cell 92(5):593-596, 1998.
18. Muoio DM, Newgard CB: Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 9(3):193-205, 2008.
19. Unger RH, Orci L: Diseases of liporegulation: new perspective on obesity and related disorders. FA S E B J 15(2):312-321, 2001.
20. Ingalls AM, Dickie MM, Snell GD: Obese, a new mutation in the house mouse. J Hered 41(12):317-318, 1950.
21. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 372(6505): 425-432, 1994.
22. Munzberg H, Morrison CD: Structure, production and signaling of leptin. Metabolism 64(1):13-23, 2015.
23. Shimabukuro M, Koyama K, Chen G, Wang MY, Trieu F, Lee Y, Newgard CB, Unger RH: Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci USA 94(9):4637-4641, 1997.
24. Lee GH, Proenca R, Montez JM, Carroll KM, Darvishzadeh JG, Lee JI, Friedman JM: Abnormal splicing of the leptin receptor in diabetic mice. Nature 379(6566):632-635, 1996.
25. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, et al.: Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84(3):491-495, 1996.
26. Bock T, Pakkenberg B, Buschard K: Increased islet volume but unchanged islet number in ob/ob mice. Diabetes 52(7):1716-1722, 2003.
27. Boquist L, Hellman B, Lernmark A, Taljedal IB: Influence of the mutation "diabetes" on insulin release and islet morphology in mice of different genetic backgrounds. J Cell Biol 62(1):77-89, 1974.
28. Hull RL, Andrikopoulos S, Verchere CB, Vidal J, Wang F, Cnop M, Prigeon RL, Kahn SE: Increased dietary fat promotes islet amyloid formation and beta-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes 52(2):372-379, 2003.
29. Dalboge LS, Almholt DL, Neerup TS, Vassiliadis E, Vrang N, Pedersen L, Fosgerau K, Jelsing J: Characterisation of age-dependent beta cell dynamics in the male db/db mice. PLoS One 8(12):e82813, 2013.
30. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA: Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 31(suppl 2):S161-S164, 2008.
31. Mosser RE, Maulis MF, Moulle VS, Dunn JC, Carboneau BA, Arasi K, Pappan K, Poitout V, Gannon M: High-fat diet-induced beta-cell proliferation occurs prior to insulin resistance in C57Bl/6J male mice. Am J Physiol Endocrinol Metab 308(7):E573-E582, 2015.
32. Stamateris RE, Sharma RB, Hollern DA, Alonso LC: Adaptive beta-cell proliferation increases early in high-fat feeding in mice, concurrent with metabolic changes, with induction of islet cyclin D2 expression. Am J Physiol Endocrinol Metab 305(1):E149-E159, 2013.
33. Mezza T, Muscogiuri G, Sorice GP, Clemente G, Hu J, Pontecorvi A, Holst JJ, Giaccari A, Kulkarni RN: Insulin resistance alters islet morphology in non-diabetic humans. Diabetes 63(3):994-1007, 2014.
34. Ward WK, Johnston CL, Beard JC, Benedetti TJ, Porte D Jr: Abnormalities of islet B-cell function, insulin action, and fat distribution in women with histories of gestational diabetes: relationship to obesity. J Clin Endocrinol Metab 61(6):1039-1045, 1985.
35. Unger RH, Orci L: Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci USA 107(37):16009-16012, 2010.
36. Unger RH: Lipotoxic diseases. Annu Rev Med 53:319-336, 2002.
37. Unger RH, Clark GO, Scherer PE, Orci L: Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 1801(3):209-214, 2010.
38. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12(7):F51-F58, 1998.
39. Duan SZ, Ivashchenko CY, Whitesall SE, D'Alecy LG, Duquaine DC, Brosius FC 3rd, Gonzalez FJ, Vinson C, Pierre MA, Milstone DS, et al.: Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J Clin Invest 117(3):812-822, 2007.
40. Kim S, Huang LW, Snow KJ, Ablamunits V, Hasham MG, Young TH, Paulk AC, Richardson JE, Affourtit JP, Shalom-Barak T, et al.: A mouse model of conditional lipodystrophy. Proc Natl Acad Sci USA 104(42):16627-16632, 2007.
41. Wang F, Mullican SE, DiSpirito JR, Peed LC, Lazar MA: Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPAR-gamma. Proc Natl Acad Sci USA 110(46):18656-18661, 2013.
42. Granner DK, Wang JC, Yamamoto KR: Regulatory actions of glucocorticoid hormones: from organisms to mechanisms. Adv Exp Med Biol 872:3-31, 2015.
43. Nieman LK: Cushing's syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol 173(4):M33-M38, 2015.
44. Collier JJ, Scott DK: Sweet changes: glucose homeostasis can be altered by manipulating genes controlling hepatic glucose metabolism. Mol Endocrinol 18(5):1051-1063, 2004.
45. O'Brien RM, Printz RL, Halmi N, Tiesinga JJ, Granner DK: Structural and functional analysis of the human phosphoenolpyruvate carboxykinase gene promoter. Biochim Biophys Acta 1264(3):284-288, 1995.
46. Beard JC, Halter JB, Best JD, Pfeifer MA, Porte D Jr: Dexamethasone-induced insulin resistance enhances B cell responsiveness to glucose level in normal men. Am J Physiol 247(5 Pt 1):E592-E596, 1984.
47. Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R: Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans. Diabetologia 36(1):84-87, 1993.
48. Rafacho A, Marroqui L, Taboga SR, Abrantes JL, Silveira LR, Boschero AC, Carneiro EM, Bosqueiro JR, Nadal A, Quesada I: Glucocorticoids invivo induce both insulin hypersecretion and enhanced glucose sensitivity of stimulus-secretion coupling in isolated rat islets. Endocrinology 151(1):85-95, 2010.
49. Rafacho A, Cestari TM, Taboga SR, Boschero AC, Bosqueiro JR: High doses of dexamethasone induce increased beta-cell proliferation in pancreatic rat islets. Am J Physiol Endocrinol Metab 296(4):E681-E689, 2009.
50. Karatsoreos IN, Bhagat SM, Bowles NP, Weil ZM, Pfaff DW, McEwen BS: Endocrine and physiological changes in response to chronic corticosterone: a potential model of the metabolic syndrome in mouse. Endocrinology 151(5):2117-2127, 2010.
51. Fransson L, Franzen S, Rosengren V, Wolbert P, Sjoholm A, Ortsater H: Beta-cell adaptation in a mouse model of glucocorticoid-induced metabolic syndrome. J Endocrinol 219(3):231-241, 2013.
52. Woo YC, Xu A, Wang Y, Lam KS: Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol (Oxf) 78(4): 489-496, 2013.
53. Itoh N, Ornitz DM: Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 149(2):121-130, 2011.
54. Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, Xiao J, Wang X, Feng W, Li X: Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 5(12):e15534, 2010.
55. Durovcova V, Marek J, Hana V, Matoulek M, Zikan V, Haluzikova D, Kavalkova P, Lacinova Z, Krsek M, Haluzik M: Plasma concentrations of fibroblast growth factors 21 and 19 in patients with Cushing's syndrome. Physiol Res 59(3):415-422, 2010.
56. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS, et al.: Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57(5):1246-1253, 2008.
57. Dostalova I, Kavalkova P, Haluzikova D, Lacinova Z, Mraz M, Papezova H, Haluzik M: Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 93(9):3627-3632, 2008.
58. Xiao Y, Xu A, Law LS, Chen C, Li H, Li X, Yang L, Liu S, Zhou Z, Lam KS: Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J Clin Endocrinol Metab 97(1):E54-E58, 2012.
59. Feingold KR, Grunfeld C, Heuer JG, Gupta A, Cramer M, Zhang T, Shigenaga JK, Patzek SM, Chan ZW, Moser A, et al.: FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob/ob mice from the toxicity of sepsis. Endocrinology 153(6):2689-2700, 2012.
60. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E: Fibro-blast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 150(11):4931-4940, 2009.
61. So WY, Cheng Q, Xu A, Lam KS, Leung PS: Loss of fibroblast growth factor 21 action induces insulin resistance, pancreatic islet hyperplasia and dysfunction in mice. Cell Death Dis 6:e1707, 2015.
62. Do OH, Low JT, Gaisano HY, Thorn P: The secretory deficit in islets from db/db mice is mainly due to a loss of responding beta cells. Diabetologia 57(7):1400-1409, 2014.
63. Wasserman DH: Four grams of glucose. Am J Physiol Endocrinol Metab 296(1):E11-E21, 2009.
64. Utzschneider KM, Van de Lagemaat A, Faulenbach MV, Goedecke JH, Carr DB, Boyko EJ, Fujimoto WY, Kahn SE: Insulin resistance is the best predictor of the metabolic syndrome in subjects with a first-degree relative with type 2 diabetes. Obesity (Silver Spring) 18(9):1781-1787, 2010.
65. Stenbit AE, Tsao TS, Li J, Burcelin R, Geenen DL, Factor SM, Houseknecht K, Katz EB, Charron MJ: GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes. Nat Med 3(10):1096-1101, 1997.
66. Dai C, Brissova M, Reinert RB, Nyman L, Liu EH, Thompson C, Shostak A, Shiota M, Takahashi T, Powers AC: Pancreatic islet vasculature adapts to insulin resistance through dilation and not angiogenesis. Diabetes 62(12): 4144-4153, 2013.
67. Hrdlicka M, Dudova I: Atypical antipsychotics in the treatment of early-onset schizophrenia. Neuropsychiatr Dis Treat 11:907-913, 2015.
68. Kurz M, Hummer M, Oberbauer H, Fleischhacker WW: Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology (Berl) 118(1):52-56, 1995.
69. Rojo LE, Gaspar PA, Silva H, Risco L, Arena P, Cubillos-Robles K, Jara B: Metabolic syndrome and obesity among users of second generation antipsy-chotics: A global challenge for modern psychopharmacology. Pharmacol Res 101:74-85, 2015.
70. Newcomer JW: Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68(suppl 4):8-13, 2007.
71. Dwyer DS, Donohoe D: Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav 75(2):255-260, 2003.
72. Abdelrahim EA: Histopathological change of the endocrine pancreas in male albino rat treated with the atypical antipsychotic clozapine. Rom J Morphol Embryol 54(2):385-394, 2013.
73. Lambert BL, Chou CH, Chang KY, Tafesse E, Carson W: Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims. Pharmacoepidemiol Drug Saf 14(6):417-425, 2005.
74. Alonso LC, Yokoe T, Zhang P, Scott DK, Kim SK, O'Donnell CP, Garcia-Ocana A: Glucose infusion in mice: a new model to induce beta-cell replication. Diabetes 56(7):1792-1801, 2007.
75. Yamashita S, Tobinaga T, Ashizawa K, Nagayama Y, Yokota A, Harakawa S, Inoue S, Hirayu H, Izumi M, Nagataki S: Glucose stimulation of protoonco-gene expression and deoxyribonucleic acid synthesis in rat islet cell line. Endocrinology 123(4):1825-1829, 1988.
76. Greenbaum CJ, Havel PJ, Taborsky GJ Jr, Klaff LJ: Intra-islet insulin permits glucose to directly suppress pancreatic A cell function. J Clin Invest 88(3):767-773, 1991.
77. Sasaki N, Iwase M, Uchizono Y, Nakamura U, Imoto H, Abe S, Iida M: The atypical antipsychotic clozapine impairs insulin secretion by inhibiting glucose metabolism and distal steps in rat pancreatic islets. Diabetologia 49(12):2930-2938, 2006.
78. Kasper SO, Castle SM, Daley BJ, Enderson BL, Karlstad MD: Blockade of the renin-angiotensin system improves insulin sensitivity in thermal injury. Shock 26(5):485-488, 2006.
79. Kasper SO, Phillips EE, Castle SM, Daley BJ, Enderson BL, Karlstad MD: Blockade of the Renin-Angiotensin system improves insulin receptor signaling and insulin-stimulated skeletal muscle glucose transport in burn injury. Shock 35(1):80-85, 2011.
80. Sugita H, Kaneki M, Sugita M, Yasukawa T, Yasuhara S, Martyn JA: Burn injury impairs insulin-stimulated Akt/PKB activation in skeletal muscle. Am J Physiol Endocrinol Metab 288(3):E585-E591, 2005.
81. Ikezu T, Okamoto T, Yonezawa K, Tompkins RG, Martyn JA: Analysis of thermal injury-induced insulin resistance in rodents. Implication of postre-ceptor mechanisms. J Biol Chem 272(40):25289-25295, 1997.
82. Scheen AJ: Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 64(22):2537-2565, 2004.
83. Bucher M, Ittner KP, Hobbhahn J, Taeger K, Kurtz A: Downregulation of angiotensin II type 1 receptors during sepsis. Hypertension 38(2):177-182, 2001.
84. Hilton JG, Marullo DS: Trauma induced increases in plasma vasopressin and angiotensin II. Life Sci 41(19):2195-2200, 1987.
85. Liu D, Yang Z, Li A: [Plasma renin activity (PRA), angiotensin II (AII), atrial natriuretic peptide (ANP) and AII/ANP ratio in severely burned patients]. Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi 10(2):117-120, 1994.
86. Sauter NS, Thienel C, Plutino Y, Kampe K, Dror E, Traub S, Timper K, Bedat B, Pattou F, Kerr-Conte J, et al.: Angiotensin II induces interleukin-1beta-mediated islet inflammation and beta-cell dysfunction independently of vaso-constrictive effects. Diabetes 64(4):1273-1283, 2015.
87. Lau T, Carlsson PO, Leung PS: Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 47(2):240-248, 2004.
88. Tahmasebi M, Puddefoot JR, Inwang ER, Vinson GP: The tissue renin-angiotensin system in human pancreas. J Endocrinol 161(2):317-322, 1999.
89. Shoemaker R, Yiannikouris F, Thatcher S, Cassis L: ACE2 deficiency reduces beta-cell mass and impairs beta-cell proliferation in obese C57BL/6 mice. Am J Physiol Endocrinol Metab 309(7):E621-E631, 2015.
90. Carlsson PO, Berne C, Jansson L: Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41(2):127-133, 1998.
91. Ballian N, Brunicardi FC: Islet vasculature as a regulator of endocrine pancreas function. World J Surg 31(4):705-714, 2007.
92. Vollmar B, Franke K, Menger MD: Nutritive perfusion of pancreatic endocrine tissue during hemorrhagic hypotension: how differ islets in situ from islet isografts? Shock 30(4):428-433, 2008.
93. Watanabe Y, Singamsetty S, Zou B, Guo L, Stefanovski D, Alonso LC, Garcia-Ocana A, O'Donnell CP, McVerry BJ: Exogenous glucose administration impairs glucose tolerance and pancreatic insulin secretion during acute sepsis in non-diabetic mice. PLoS One 8(6):e67716, 2013.
94. Singamsetty S, Shah FA, Guo L, Watanabe Y, McDonald S, Sharma R, Zhang Y, Alonso LC, O'Donnell CP, McVerry BJ: Early initiation of low-level parenteral dextrose induces an accelerated diabetic phenotype in septic C57BL/6J mice. Appl Physiol Nutr Metab 41(1):12-19, 2016.
95. Burke SJ, Stadler K, Lu D, Gleason E, Han A, Donohoe DR, Rogers RC, Hermann GE, Karlstad MD, Collier JJ: IL-1beta reciprocally regulates chemo-kine and insulin secretion in pancreatic beta-cells via NF-kappaB. Am J Physiol Endocrinol Metab 309(8):E715-E726, 2015.
96. Corbett JA, McDaniel ML: Intraislet release of interleukin 1 inhibits beta cell function by inducing beta cell expression of inducible nitric oxide synthase. J Exp Med 181(2):559-568, 1995.
97. Rieck S, Kaestner KH: Expansion of beta-cell mass in response to pregnancy. Trends Endocrinol Metab 21(3):151-158, 2010.
98. Cozar-Castellano I, Fiaschi-Taesch N, Bigatel TA, Takane KK, Garcia-Ocana A, Vasavada R, Stewart AF: Molecular control of cell cycle progression in the pancreatic beta-cell. Endocr Rev 27(4):356-370, 2006.
99. Sachdeva MM, Stoffers DA: Minireview: meeting the demand for insulin: molecular mechanisms of adaptive postnatal beta-cell mass expansion. Mol Endocrinol 23(6):747-758, 2009.
100. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Aleman JO, Suzuki R, Scapa EF, Agarwal C, Carey MC, Stephanopoulos G, et al.: Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 7(2):125-134, 2008.
101. Biddinger SB, Haas JT, Yu BB, Bezy O, Jing E, Zhang W, Unterman TG, Carey MC, Kahn CR: Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med 14(7):778-782, 2008.
102. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn CR: Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 6(1): 87-97, 2000.
103. Kulkarni RN, Jhala US, Winnay JN, Krajewski S, Montminy M, Kahn CR: PDX-1 haploinsufficiency limits the compensatory islet hyperplasia that occurs in response to insulin resistance. J Clin Invest 114(6):828-836, 2004.
104. Oliver-Krasinski JM, Stoffers DA: On the origin of the beta cell. Genes Dev 22(15):1998-2021, 2008.
105. Taylor BL, Liu FF, Sander M: Nkx6.1 is essential for maintaining the functional state of pancreatic beta cells. Cell Rep 4(6):1262-1275, 2013.
106. Schisler JC, Jensen PB, Taylor DG, Becker TC, Knop FK, Takekawa S, German M, Weir GC, Lu D, Mirmira RG, et al.: The Nkx6.1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells. Proc Natl Acad Sci USA 102(20):7297-7302, 2005.
107. Guo S, Dai C, Guo M, Taylor B, Harmon JS, Sander M, Robertson RP, Powers AC, Stein R: Inactivation of specific beta cell transcription factors in type 2 diabetes. J Clin Invest 123(8):3305-3316, 2013.
108. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52(1):102-110, 2003.
109. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R: In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology 21(5):1465-1468, 1995.
110. Hughes KJ, Meares GP, Chambers KT, Corbett JA: Repair of nitric oxide-damaged DNA in beta-cells requires JNK-dependent GADD45alpha expression. J Biol Chem 284(40):27402-27408, 2009.
111. Pajvani UB, Accili D: The new biology of diabetes. Diabetologia 58(11): 2459-2468, 2015.
112. Weir GC, Aguayo-Mazzucato C, Bonner-Weir S: beta-cell dedifferentiation in diabetes is important, but what is it? Islets 5(5):233-237, 2013.
113. Talchai C, Xuan S, Lin HV, Sussel L, Accili D: Pancreatic beta cell dediffer-entiation as a mechanism of diabetic beta cell failure. Cell 150(6):1223-1234, 2012.
114. Wang Z, York NW, Nichols CG, Remedi MS: Pancreatic beta cell dediffer-entiation in diabetes and redifferentiation following insulin therapy. Cell Metab 19(5):872-882, 2014.
115. DeFronzo RA, Abdul-Ghani MA: Preservation of beta-cell function: the key to diabetes prevention. J Clin Endocrinol Metab 96(8):2354-2366, 2011.
116. Burke SJ, Collier JJ: Insulitis and diabetes: a perspective on islet inflammation. Immunome Research 10:e002, 2014.
117. Kahn SE, Zraika S, Utzschneider KM, Hull RL: The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 52(6):1003-1012, 2009.
118. Doria A, Patti ME, Kahn CR: The emerging genetic architecture of type 2 diabetes. Cell Metab 8(3):186-200, 2008.
119. Gooding JR, Jensen MV, Newgard CB: Metabolomics applied to the pancreatic islet. Arch Biochem Biophys 589:120-130, 2016.
120. Collier JJ, Burke SJ, Eisenhauer ME, Lu D, Sapp RC, Frydman CJ, Campagna SR: Pancreatic beta-cell death in response to pro-inflammatory cytokines is distinct from genuine apoptosis. PLoS One 6(7):e22485, 2011.
121. El Ouaamari A, Zhou JY, Liew CW, Shirakawa J, Dirice E, Gedeon N, Kahraman S, De Jesus DF, Bhatt S, Kim JS, et al.: Compensatory Islet response to insulin resistance revealed by quantitative proteomics. J Proteome Res 14(8):3111-3122, 2015.
122. Horn S, Kirkegaard JS, Hoelper S, Seymour PA, Rescan C, Nielsen JH, Madsen OD, Jensen JN, Kruger M, Gr Nborg M, et al.: Research resource: a dual proteomic approach identifies regulated islet proteins during beta cell mass expansion in vivo. Mol Endocrinol 30(1):133-143, 2016.